Ask AI
Therapeutic Strategies in Myeloma

CE / CME

Therapeutic Strategies in Multiple Myeloma: Overview of Current and Emerging Treatment Options

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: April 26, 2023

Expiration: April 25, 2024

Activity

Progress
1
Course Completed

Introduction

In this module, Shaji K. Kumar, MD discusses key data across the treatment spectrum of multiple myeloma (MM), including emerging targets and therapies.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset supplementing the discussion by the faculty. This slideset may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional (HCP), how many patients with MM do you provide care for in a typical month?

Would this patient with SMM be a candidate for initiation of treatment at this time?

A 62-year-old male with past medical history of GERD is newly diagnosed with MM. He also has high-risk cytogenetics with t(4;14) and del(17p) and is determined to be fit for autologous stem cell transplant (ASCT). Based on available data, which of the following regimens would be preferred for this patient?

In your current clinical practice, what would you recommend for this patient after multiple relapses?

Which of the following investigational bispecific antibodies targeting BCMA could be an option on clinical trial for patients who are refractory to an IMiD, PI, and anti-CD38 mAb?